[Immunotherapy with subcutaneous recombinant IL-2 and interferon combined with surgery in advanced stage carcinoma of the kidney].
Twelve consecutive patients with metastatic renal cell carcinoma were submitted to an integrate treatment plan of immunotherapy with subcutaneous IL-2 and IFN and radical surgery in a pilot study. Partial response were observed in 2 patients, stable disease in 5 patients and progression of disease under treatment were observed in 5. Two RP were maintained for 12 and 18+ months and 1 SD is maintained at 12+ months. Treatment was well tolerated without significant toxicity. Integrated radical surgery and immunotherapy with s.c. IL-2 and IFN can produce occasionally protracted clinical responses.
Maffezzini
M
M
Istituto di Clinica Urologica dell'Università di Trieste.
Simonato
A
A
Lodolo
C
C
Carmignani
G
G
D000368:Aged; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins; D007372:Interferons